Amgen Inc.

Robert P Farrell

Julio Cesar Medina

Lawrence R McGee

Jonathan B Houze

Ning Chen

Xiaohui Du

Xiaoqi Chen

Nobuko Nishimura

Kevin Chao Yang

Matthew R Kaller

Jeffrey Thomas Mihalic

Zhihua Ma

David John Kopecky

Zice Fu

Ted Charles Judd

Paul John Dransfield

Vatee Pattaropong

Xiaodong Wang

Daniel B Horne

Richard V Connors

Jeffrey Deignan

Julie Anne Heath

Steven H Olson

Mikkel V Debenedetto

Su-Jen Lai

Simon J Hedley

Frank Kayser

Alan C Cheng

Gayathri Swaminath

Wen-Chen Yeh

Aarif Yusuf Khakoo

Yinhong Chen

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Growing community of inventors

Thousand Oaks, CA, United States of America

Robert P Farrell